-
Innovation Ranking
Innovation Ranking – KYORIN Holdings Inc
KYORIN Holdings Inc (Kyorin) is a holding company that controls, administers and supports its group companies that conduct various businesses by holding the shares of those companies. The company through its subsidiaries carries out the discovery, development, manufacturing and sale of pharmaceuticals including new ethical drugs, generic drugs and the over the counter (OTC) drugs, diagnostics, reagents, intermediates, diagnostics, industrial chemicals and other products. The company markets its product under Kipres, Mucodyne, Pentasa, Uritos, Ketas, Flutiform, Milton, Rubysta and other...
-
Company Insights
Innovation and Patenting activity of KYORIN Holdings Inc Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of KYORIN Holdings Inc Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewPulmonary Sarcoidosis – Drugs In Development, 2024
Empower your strategies with our Pulmonary Sarcoidosis – Drugs In Development, 2024 report and make more profitable business decisions. Pulmonary Sarcoidosis is a rare inflammatory disease that affects the multi-organs predominantly lungs and intrathoracic lymph nodes. It is characterized by the presence of granulomas in which group of cells form clusters of inflamed tissue. Younger and middle-aged groups are commonly affected and there is no specific origin causing this condition. It is differentiated into five different stages from stage 0 to...
-
Product Insights
NewSarcoidosis – Drugs In Development, 2024
Empower your strategies with our Sarcoidosis – Drugs In Development, 2024 report and make more profitable business decisions. Sarcoidosis is a systemic inflammatory disease that can affect any organ. It is characterized by the development and growth of tiny lumps of cells called granulomas. The disease usually begins in the lungs, skin, or lymph nodes. The cause of sarcoidosis is unknown. Signs and symptoms of sarcoidosis vary based on the location of the granulomas and the severity of the condition. The...
-
Product Insights
NewInterstitial Lung Diseases (Diffuse Parenchymal Lung Disease) – Drugs In Development, 2024
Empower your strategies with our Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) – Drugs In Development, 2024 report and make more profitable business decisions. Interstitial lung disease (ILD) is a term that covers a variety of disorders that cause scarring or inflammation of the lung tissue. The scarring or inflammation affects the ability of the lungs to transfer oxygen to the blood. ILD can be caused by many factors, such as exposure to environmental toxins, certain medications, autoimmune diseases, infections, or...
-
Product Insights
NewGlaucoma – Drugs In Development, 2024
Empower your strategies with our Glaucoma – Drugs In Development, 2024 report and make more profitable business decisions. Glaucoma is a disease of the eye in which fluid pressure within the eye rises. The exact cause of optic nerve damage from glaucoma is not fully understood, but involves mechanical compression and/or decreased blood flow to the optic nerve. The most important risk factors include age, elevated eye pressure, African ancestry, thin cornea, and family history of glaucoma. Signs and symptoms include...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KPRA-218 in Rhinovirus Infections
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. KPRA-218 in Rhinovirus Infections Drug Details: KPRA-218 is under development for the treatment of rhinovirus...